TABLE 2.
Demographics, laboratory test in nine patients with chilblain‐like‐lesions
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | |
|---|---|---|---|---|---|---|---|---|---|
| Age/sex | 5/M | 12/F | 11/M | 11/M | 8/F | 13/F | 14/F | 15/M | 14/F |
| Nasopharyngeal swab | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| Serology SARS‐CoV‐2 infection (IgM‐IgG) | Negative | Negative | Negative | Negative | IgM 1 AU/mL (N.V. <1) | Negative | Negative | Negative | Negative |
| Coagulation | D‐dimer 0.99 (N.V. 0.0‐0.5) | D‐dimer 0.60 (N.V. 0.0‐0.5) | Normal | Normal | Normal | Normal | D‐dimer 0.80 (N.V. 0.0‐0.5) | Normal | Normal |
| Immunoglobulin | Normal | Normal | Normal | Normal | Normal | Normal | Normal | Normal | Normal |
| ANA, ENA, nDNA, SCl70, RF | Negative | ANA 1:160 speckled | Negative | Negative | ANA 1:160 speckled | Negative | ANA 1:5120 speckled FR 30.2 (0‐14) | ANA 1:320 speckled | Negative |
| aPL, aCL LAC, anti‐β2GP1 | Negative | aPL IgM 27.9 U/mL (N.V. <25) | Negative | Negative | Negative | Negative | Negative | aPL IgM 36.7 U/mL (N.V. <25) | aPL IgM 51.1 U/mL (N.V. <25) |
| Complement levels | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| Urine test | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
| ESR/PCR | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
Abbreviations: aCL, anti‐cardiolipin; ANA, antinuclear antibodies; anti‐β2GP1, anti β‐2‐glycoprotein1; aPL, antiphospholipid antibodies (Normal values <25 U/mL); ENA, extractable nuclear antigens; FR, rheumatoid factor; LAC, lupus anticoagulant; nDNA, double stranded DNA; NV, normal value; SCL70, anti‐topoisomerase.